News
ADVI in the News
Are payers optimistic about biosimilars’ savings?
ADVI Senior Director Valerie Reynolds (now with Genentech) was interviewed on issue related to follow on biologics.
Trump election sends aftershocks through biotech sector
ADVI’s CEO Marc Samuels was interviewed about the new Trump Administration and various healthcare issues including reform of drug pricing.
Marc Samuels Quoted in Pink Sheet
“I believe there are things that will change. But I’m not as bullish as some drug [industry] colleagues that things will just disappear,” Marc Samuels, founder and CEO of the ADVI consulting firm, said in an interview. “There may be a growing number of advisors in his camp, as well as the president-elect himself, that would not want to get rid of CMMI wholesale,” ADVI’s Samuels suggests.
Valerie Reynolds Quoted in Managed Healthcare Executive.com
“Inflectra . . . would be the second biologic to launch under the biosimilars pathway created by the Affordable Care Act, Zarxio [filgrastim-sndz] being the first,” according to Valerie Reynolds, senior director at ADVI. Sandoz, Inc.’s Zarxio is biosimilar to Amgen Inc.’s cancer drug Neupogen (filgrastim). “Inflectra would be the first therapeutic and the first immunology product. [The drug’s] launch would provide additional data on how biosimilars will affect the market,” Reynolds says. “In 2017, we are expecting biosimilar launches that will compete with infliximab—adalimumab and etanercept—biosimilars that will be reimbursed under the pharmacy benefit instead of the medical benefit.”
Lindsey McCandless Quoted in CNBC.com
Lindsey McCandless, associate director of ADVI Health, a boutique health-care advisory firm, said that for consumers "the star ratings only provides a snapshot of quality care." She also said, "Patients must keep in mind that they may not be based on what is most important to their needs."
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.